Reductil

GPTKB entity

Statements (59)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:approves gptkb:various_countries
gptkb:1997
gptkbp:associated_with risk of stroke
risk of heart attack
gptkbp:available_in oral form
gptkbp:brand gptkb:Reductil
gptkb:Meridia
gptkbp:class anorectic agent
gptkbp:clinical_trial weight management studies
gptkbp:contraindication gptkb:Cardiology
pregnancy
breastfeeding
eating disorders
history of stroke
gptkbp:discontinued gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:New_Zealand
gptkb:United_Kingdom
gptkb:United_States
gptkbp:dosage_form 10 mg
15 mg
gptkbp:duration short-term use
long-term use not recommended
gptkbp:formulation gptkb:capsule
https://www.w3.org/2000/01/rdf-schema#label Reductil
gptkbp:ingredients synthetic compound
sibutramine
gptkbp:interacts_with gptkb:beer
MAO inhibitors
other weight loss medications
gptkbp:is_monitored_by required during treatment
gptkbp:marketed_as gptkb:Abbott_Laboratories
gptkbp:mechanism_of_action gptkb:depression
gptkbp:regulatory_compliance prescription only
gptkbp:related_to obesity treatment
gptkbp:replaces gptkb:2010
some markets
gptkbp:side_effect dizziness
fatigue
headache
nausea
insomnia
constipation
dry mouth
sweating
increased heart rate
palpitations
gptkbp:storage room temperature
dry place
gptkbp:suitable_for gptkb:children
adolescents
elderly patients
gptkbp:used_for weight loss
gptkbp:weight_loss_effect varies by individual
gptkbp:bfsParent gptkb:Sibutramine
gptkb:Sibutramine_hydrochloride
gptkbp:bfsLayer 6